Woman Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
To collect and assess safety information for the double-blinded treatment period ending 5 years post-randomization regarding deaths, SAEs, adverse events requiring adjudication, and skin ECIs in subjects who were randomized and tookat least one dose of blinded study medication, then discontinued from study drug but have not completed follow-up through the 5-year blinded treatment period of Protocol 018 and its 1stextension. These data will be analyzed togetherwithdata fromsubjects who have completed 5 years of blinded study medication
Inclusion criteria
- Osteoporosis